Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor

作者：Ogasawara Masahito; Nakamura Yutaka^*; Morikawa Naoto; Nitanai Hiroo; Moriguchi Satoshi; Chiba Ryosuke; Saito Heisuke; Ohta Mika; Tanita Tatsuo; Sugai Tamotsu; Maeyama Kazutaka; Yamauchi Kohei; Takaoka Yutaka

来源：Cancer Chemotherapy and Pharmacology, 2016, 77(5): 1019-1029.

DOI：10.1007/s00280-016-3021-y

• Epidermal growth factor receptor
• Tyrosine kinase inhibitor
• Single-codon deletion
• Exon 19
• Gefitinib

Purpose Epidermal growth factor receptor (EGFR) gene mutations are the most established genomic biomarkers for the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs). The most frequent deletion in exon 19 is delE746_750, followed by del747_753insS and del747_750insP. Since investigations of delE746 have not been reported previously, it is unclear if delE746 conveys sensitivity to TKI effect of TKI on EGFR delE746. The objective was to characterize delE746 of the EGFR gene and to explore the effects of TKIs on the delE746.
Methods We assessed the ability of gefitinib to inhibit phosphorylation of clonal L929 cell lines expressing EGFR with delE746. 3-D structures of the EGFR proteins were also used to investigate the interaction with gefitinib.
Results The delE746 mutant EGFR-expressing cells exhibited gefitinib-sensitive autophosphorylation, which altered the structure of the EGFR and increased the instances of docking during docking simulations of gefitinib with the EGFR-TK. This mutant revealed that it exhibited molecular conformation alterations, and more frequent binding with gefitinib compared to wild-type EGFR. We administered EGFR-TKI, gefitinib to a Japanese woman with lung cancer that contained delE746. The patient achieved partial response after a 5 month of treatment with gefitinib. Conclusion Our study revealed biological, structural, and probably clinical features of the delE746 form of EGFR.

• 出版日期2016-5